[{"address1": "2533 South Coast Highway 101", "address2": "Suite 210", "city": "Cardiff", "state": "CA", "zip": "92007", "country": "United States", "phone": "858 400 8470", "website": "https://www.viracta.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Andrew Rothera", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 959333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Biljana  Nadjsombati Pharm.D.", "title": "Senior Vice President of Pharmaceutical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert C. McRae", "title": "Vice President of Operations & Strategic Alliances", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.84, "open": 0.84, "dayLow": 0.8, "dayHigh": 0.84, "regularMarketPreviousClose": 0.84, "regularMarketOpen": 0.84, "regularMarketDayLow": 0.8, "regularMarketDayHigh": 0.84, "beta": 0.36, "forwardPE": -0.72339284, "volume": 32999, "regularMarketVolume": 32999, "averageVolume": 114843, "averageVolume10days": 48680, "averageDailyVolume10Day": 48680, "bid": 0.7683, "ask": 0.8594, "bidSize": 100, "askSize": 100, "marketCap": 31818498, "fiftyTwoWeekLow": 0.43, "fiftyTwoWeekHigh": 2.38, "fiftyDayAverage": 0.937, "twoHundredDayAverage": 0.88055, "currency": "USD", "enterpriseValue": 9000526, "floatShares": 24551555, "sharesOutstanding": 39272400, "sharesShort": 686731, "sharesShortPriorMonth": 634263, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0175, "heldPercentInsiders": 0.027609998, "heldPercentInstitutions": 0.52794, "shortRatio": 4.96, "shortPercentOfFloat": 0.0222, "bookValue": 0.329, "priceToBook": 2.4626138, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -51058000, "trailingEps": -1.32, "forwardEps": -1.12, "pegRatio": -0.01, "lastSplitFactor": "1:10", "lastSplitDate": 1599091200, "enterpriseToEbitda": -0.179, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VIRX", "underlyingSymbol": "VIRX", "shortName": "Viracta Therapeutics, Inc.", "longName": "Viracta Therapeutics, Inc.", "firstTradeDateEpochUtc": 1127827800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ed5f69f9-939f-3d89-84c4-600b43f665a9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8102, "targetHighPrice": 13.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.0, "targetMedianPrice": 5.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 53826000, "totalCashPerShare": 1.371, "ebitda": -50201000, "totalDebt": 25556000, "quickRatio": 1.41, "currentRatio": 1.432, "debtToEquity": 139.505, "returnOnAssets": -0.41502, "returnOnEquity": -1.28574, "freeCashflow": -21787124, "operatingCashflow": -39892000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]